Christopher Moreau, CEO & Director of Algernon Pharmaceuticals (CSE: AGN | OTCQB: AGNPF | XFRA: AGN0) highlights that the company has been granted permission to conduct a Phase 1 clinical study of DMT for the potential treatment of stroke.

Algernon is a Canadian clinical-stage drug development company investigating multiple drugs with global unmet medical needs.